NCT02640222 is a clinical trial of VKA in Anticoagulation, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT02640222?

NCT02640222 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT02640222?

Interventions in NCT02640222: VKA, Apixaban, dabigatran, rivaroxaban.

What condition does NCT02640222 study?

NCT02640222 studies Anticoagulation.

Is NCT02640222 still recruiting?

NCT02640222 is currently completed. Last updated 18 May 2022.

Last reviewed 2022-05-18 · How we verify

NCT02640222

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Completed Last updated 18 May 2022

What this trial tests

trial testing VKA in Anticoagulation in 321,501 participants. Completed in 31 December 2019.

Timeline

1 January 2014

Primary endpoint
31 December 2016

31 December 2019

Quick facts

Lead sponsor	Bristol-Myers Squibb
Status	Completed
Study type	OBSERVATIONAL
Enrollment	321,501
Start date	1 January 2014
Primary completion	31 December 2016
Estimated completion	31 December 2019
Sites	1 location across France

Drugs / interventions tested

VKA (vka) — full drug profile →
Apixaban (apixaban) — full drug profile →
dabigatran (DABIGATRAN) — full drug profile →
rivaroxaban (rivaroxaban) — full drug profile →

Conditions studied

Anticoagulation — all drugs for Anticoagulation →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Anticoagulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E, Danchin N, Mahé I, Hanon O, et al · · 2020 · cited 48× · PMID 32539675 · DOI 10.1161/strokeaha.120.028825
EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study.
Picard F, Van Ganse E, Ducrocq G, Danchin N, et al · · 2019 · cited 3× · PMID 31313832 · DOI 10.1002/clc.23231

Verify or expand the search:

Other trials of VKA

Trials testing the same drug.

NCT07172022 — A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) · Phase 2 · withdrawn
NCT07011095 — DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial · EARLY_PHASE1 · not yet recruiting
NCT05838664 — A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) · completed
NCT04618913 — Anticoagulation in Patients With Venous Thromboembolism and Cancer · active not recruiting
NCT03362788 — The Greek AntiPlatElet Atrial Fibrillation Registry. · completed

Other recruiting trials for Anticoagulation

Currently open trials in the same condition.

NCT05782270 — Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy · Phase 4 · recruiting
NCT07129395 — Anticoagulation Adherence Measurement Strategies · active not recruiting
NCT04539301 — Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux L · recruiting
NCT03910933 — Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02640222 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 18 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02640222.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing